EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT BURKITT/BURKITT-LIKE LYMPHOMA: A SYSTEMATIC REVIEW

Authors

  • U. Joshi Department of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA
  • R. Subedi Department of Internal Medicine, Unity Hospital — Rochester Regional Health, Rochester, NY 14626, USA
  • G. Nepal Department of Internal Medicine, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu 44600, Nepal
  • S. Gyawali Department of Internal Medicine, Sukraraj Tropical and Infectious Disease Hospital, Kathmandu 44600, Nepal
  • V. Agrawal Department of Internal Medicine, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu 44600, Nepal
  • B.S. Poudyal Clinical Hematology and Bone Marrow Transplant Unit, Civil Service Hospital, Kathmandu 44600, Nepal
  • V.R. Bhatt Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA - Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA
  • Ch.R. D’Angelo Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA -Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18599

Keywords:

autologous., Burkitt lymphoma., chemotherapy, hematopoietic stem cell transplantation, survival outcome

Abstract

Background: Burkitt and Burkitt like lymphoma (BL/BLL) are highly proliferative germinal or post-germinal B cell tumors. Few studies have evaluated the impact of autologous stem cell transplantation (ASCT) on disease outcomes. Aim: We performed a systematic review to analyze the efficacy of ASCT as frontline consolidation and for treatment of relapsed/refractory cases in adult BL/BLL. Materials and Methods: Eligible studies with clear outcome measures on the efficacy of ASCT in adult patients with BL/BLL were identified through systematic search. The overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), and progression/relapse were used to assess the efficacy. Results: For patients who underwent ASCT in first CR, 5-year PFS and OS ranged between 70–78% and 70–83% respectively. For relapsed/refractory disease, 5-year PFS and OS were 27% and 31%, respectively. Patients undergoing ASCT for chemoresistant disease fared poorly with 3-year OS of 7% vs 37% for chemosensitive disease (p ≤ 0.00001). The overall response rate to ASCT for patients transplanted in first CR ranged between 71% and 93% and was 37% for patients who were transplanted in disease status other than first CR. Disease progression/relapse was observed in 16–29% of the patients transplanted in first CR, and 55% to 60% in relapsed disease. Conclusion: We found insufficient evidence to support ASCT over chemotherapy alone in the first remission for adult BL/BLL. Evidence supports guidelines recommending ASCT for chemosensitive disease but suggests there is no benefit to ASCT for chemoresistant disease.

References

Molyneux EM, Rochford R, Griffin B, et al. Burkitt’s lymphoma. Lancet 2012; 379: 1234–44. https://doi.org/10.1016/S0140-6736(11)61177-X

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375–90. https://doi.org/10.1182/blood-2016-01-643569

Freedman AS, Aster JC, Rosmarin AG. Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma. Uptodate. Post TW (ed): UpToDate Inc, Waltham, MA. 2020. Available at https://www.uptodate.com/contents/ epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-burkitt-lymphoma

Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 2402–11. https://doi.org/10.1016/S0140-6736(15)01317-3

Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood 2021; 137: 743–50. https://doi.org/10.1182/blood.2019004099

[Guideline] NCCN Clinical Practice Guidelines in Oncology. B-cell Lymphomas. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/ physician_gls/pdf/nhl.pdf. Version 4.2021 — May 5, 2021; Accessed: May 19, 2021

Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 2014; 165: 102–11. https://doi.org/10.1111/bjh.12736

Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569–80. https://doi.org/10.1002/cncr.21776

Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004; 100: 1438–48. https://doi.org/10.1002/cncr.20143

Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112: 2248–60. https://doi.org/10.1182/blood-2008-03-145128

Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264–74. https://doi.org/10.1093/annonc/mdf253

Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925–34. https://doi.org/10.1200/JCO.1996.14.3.925

Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. New Engl J Med 2013; 369: 1915–25. https://doi.org/10.1056/NEJMoa1308392

Divine M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005; 16:1928–35. https://doi.org/10.1093/annonc/mdi403

Evens AM, Danilov A, Jagadeesh D, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 2021; 137: 374–86. https://doi.org/10.1182/blood.2020006926

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151:264–9. https://doi.org/10.7326/0003-4819-151-4-200908180-00135

Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res 2013; 19: 2629–36. https://doi.org/10.1158/1078-0432.CCR-12-2935

Subedi R, Joshi U, Gyawali S, et al. Copanlisib in non-Hodgkin’s lymphoma and solid tumors: An efficacy and safety analysis. Ann Cancer Res Ther 2021; 29: 85–95. https://doi.org/10.4993/acrt.29.85

Maramattom LV, Hari PN, Burns LJ, et al. Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl 2013; 19: 173–9. https://doi.org/10.1016/j.bbmt.2012.11.016

Appelbaum FR, Deisseroth AB, Graw Jr RG, et al. Prolonged complete remission following high dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer 1978; 41: 1059–63. https://doi.org/10.1002/1097-0142(197803) 41:3<1059::aid-cncr2820410339>3.0.co;2-n

van Imhoff GW, van der Holt B, MacKenzie MA, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005; 19: 945–52. https://doi.org/10.1038/sj.leu.2403733

Smeland S, Blystad AK, Kvaløy SO, et al. Treatment of Burkitt’s/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 2004; 15: 1072–8. https://doi.org/10.1093/annonc/mdh262

Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma–outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996; 14: 2465–72. https://doi.org/10.1200/JCO.1996.14.9.2465

Ishizawa K. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-6. Burkitt lymphoma. Int J Hematol 2019; 110: 265–71. https://doi.org/10.1007/s12185-019-02697-9

Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 2017; 92: E114. https://doi.org/10.1002/ajh.24720

Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New Engl J Med 1995; 333: 1540–5. https://doi.org/10.1056/NEJM199512073332305

Jourdain A, Auperin A, Minard-Colin V, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B ‘’ protocols. A Societe Francaise des Cancers de l’Enfant study. Haematologica 2015; 100: 810. https://doi.org/10.3324/haematol.2014.121434

Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010; 16: 223–30. https://doi.org/10.1016/j.bbmt.2009.09.021

Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations. J Nat Cancer Inst 2006; 98: 15–25. https://doi.org/10.1093/jnci/djj001

Downloads

Published

26.05.2023

How to Cite

Joshi, U., Subedi, R., Nepal, G., Gyawali, S., Agrawal, V., Poudyal, B., … D’Angelo, C. (2023). EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT BURKITT/BURKITT-LIKE LYMPHOMA: A SYSTEMATIC REVIEW. Experimental Oncology, 44(3), 190–197. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18599

Issue

Vol. 44 No. 3 (2022): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.